地诺单抗去哪买的到？

In China, clinical treatment methods for bone metastases are limited. Currently, the main treatment method is regular monthly intravenous administration of bisphosphonate drugs (disodium pamidronate, zoledronic acid). In severe cases, radiotherapy and other treatments can be used. However, in countries and regions such as Europe, the United States, and Hong Kong, denosumab is the first choice for the treatment of bone metastases. Multiple clinical studies have shown that denosumab is significantly more effective than zoledronic acid in patients with bone metastases from solid tumors.

Denosumab can only be given by subcutaneous injection, not by intravenous infusion, intramuscular infusion or intradermal injection. Giant cell tumor of bone: 120 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. Administer calcium and vitamin D appropriately to prevent hypocalcemia. Bone metastases from solid tumors: 120 mg subcutaneously in the upper arm, thigh, or abdomen every 4 weeks. Malignant hypercalcemia: 20 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

Nursing mothers: It is not known whether denosumab is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions from denosumab in nursing infants, the decision whether to discontinue breastfeeding or discontinue the drug should be made taking into account the importance of the drug to the mother. Based on animal studies in pregnant mice lacking the RANK/RANKL signaling pathway that have shown altered maternal mammary gland maturation, resulting in impaired postpartum lactation, maternal exposure to denosumab during pregnancy may impair mammary gland development and lactation.

Pediatric Use: The safety and effectiveness of denosumab in pediatric patients have not been established. Treatment with denosumab may impair bone growth in children with open growth plates and may inhibit delayed eruption of permanent teeth.

Although denosumab has been approved for marketing in my country, it is conditionally approved, and it is less than five months since it was launched, which means that ordinary domestic patients still do not have access to this drug. Fortunately, denosumab produced by Amgen of the United States has been launched in Turkey, and the price is the lowest in the world. The specification of denosumab in Turkey is 125mg/1ml tube/box, and the price is equivalent to RMB 3,000.

How to purchase denosumab, the original drug of American Amgen sold in Turkey:

1. You can go to Turkey to buy it in person, but this is more time-consuming and labor-intensive. The most important thing is that it is difficult to distinguish the authenticity of denosumab in the Turkish market, and it is extremely easy to be deceived.

2. Find domestic overseas medical service agencies (such as Medical Companion Travel), and let them translate the cases, contact experienced doctors in Turkish hospitals to write prescriptions, and deliver the drugs to the patients via direct mail from the Turkish pharmaceutical factory. They will also provide guidance and answer questions for the patients while taking denosumab. This is currently the most convenient and fastest solution.